Aberrant Cluster of Differentiation (CD) Marker Expression Across B-cell Chronic Lymphoproliferative Disorder Subtypes: A Single-Center Flow Cytometry Study From Sri Lanka
4 affiliations
- 1Hematology, Sri Jayewardenepura General Hospital, Colombo, LKA
- 2Hematology, University of Sri Jayewardenepura, Colombo, LKA
- 3Microbiology, University of Sri Jayewardenepura, Colombo, LKA
- 4Community Medicine, Warwick Medical School, University of Warwick, Coventry, GBR
Abstract
Introduction Flow-cytometric immunophenotyping is central to the diagnosis and subclassification of B-cell chronic lymphoproliferative disorders (B-CLPDs). In routine practice, partial antigen loss, reduced expression, and unexpected antigen acquisition may create diagnostic difficulty, particularly when tissue-based or molecular confirmation is delayed. This study describes subtype-wise aberrant cluster of differentiation (CD) marker expression patterns in B-CLPDs diagnosed by integrated morphology and multiparameter flow cytometry in a Sri Lankan tertiary-care laboratory. Methods A descriptive cross-sectional analysis was performed on 210 diagnosed B-CLPD cases. Aberrancies were categorized as unexpected expression, antigen loss, or reduced expression using predefined subtype-specific expectations, internal reference populations, and routine laboratory fluorescence-intensity interpretation. Frequencies were reported as N (%) within each subtype, with denominators specified where relevant. Because several rare subtypes had small numbers, inferential testing was restricted to selected comparable aberrancy events between chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Results CLL was the commonest subtype, comprising 94 (44.8%) cases, followed by MCL with 34 (16.2%) and the CD5-negative/CD10-negative/hairy-marker-negative B-CLPD group with 31 (14.8%). In CLL, the most frequent events were unexpected CD20 expression in 44 (46.8%) cases, reduced CD45 in 42 (44.7%), unexpected surface kappa expression in 24 (25.5%), and reduced CD23 in 24 (25.5%). MCL showed reduced CD45 in 11 (32.4%) cases, reduced CD43 in eight (23.5%), reduced CD5 in four (11.7%), unexpected CD23 in four (11.8%), unexpected CD200 in four (11.8%), and reduced FMC7 in four (11.8%). The CD5-negative/CD10-negative/hairy-marker-negative B-CLPD group was the most heterogeneous, with reduced CD200 and reduced FMC7 each occurring in 15 (48.3%) cases. Conclusion CLL was characterized mainly by unexpected CD20 expression and reduced CD45, whereas MCL most commonly showed reduced CD45 and CD43. The CD5-negative/CD10-negative/hairy-marker-negative B-CLPD group showed the greatest immunophenotypic heterogeneity, particularly reduced CD200 and FMC7. These findings demonstrate that aberrant antigen expression is subtype-associated and should be interpreted within the complete immunophenotypic profile rather than using individual markers in isolation.
Related
- Methotrexate-induced Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorder with Diffuse Ground-glass Opacities Diagnosed Using a Cryobiopsy
- Rapidly progressive adult-onset hydroa vacciniforme-like lymphoproliferative disorder associated with Epstein-Barr virus: a case report.
- Calcineurin Inhibitor–Free, mTOR‐Based Immunosuppression in Chimeric Antigen Receptor T‐Cell Therapy for Post‐Transplant Lymphoproliferative Disorder
- Overestimated Volatility Underpins Aberrant Decision Making in Bipolar I Disorder
- Central Nervous System Methotrexate-associated Lymphoproliferative Disorder Presenting with Progressive Dural Thickening
BibTeX
@article{balasuriya2026aberrant,
title = {{Aberrant Cluster of Differentiation (CD) Marker Expression Across B-cell Chronic Lymphoproliferative Disorder Subtypes: A Single-Center Flow Cytometry Study From Sri Lanka}},
author = {Thushara Balasuriya and Chamarika Moonesinghe and Neluka Fernando and Chinthika Gunasekara and Surangi Jayakody and Chitranga Kariyawasan},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.117139},
url = {https://europepmc.org/article/PMC/PMC13717810},
note = {CC BY},
}
RIS
TY - JOUR
TI - Aberrant Cluster of Differentiation (CD) Marker Expression Across B-cell Chronic Lymphoproliferative Disorder Subtypes: A Single-Center Flow Cytometry Study From Sri Lanka
AU - Thushara Balasuriya
AU - Chamarika Moonesinghe
AU - Neluka Fernando
AU - Chinthika Gunasekara
AU - Surangi Jayakody
AU - Chitranga Kariyawasan
PY - 2026
DA - 2026/09/29
JO - Cureus
DO - 10.7759/cureus.117139
UR - https://europepmc.org/article/PMC/PMC13717810
AB - Introduction Flow-cytometric immunophenotyping is central to the diagnosis and subclassification of B-cell chronic lymphoproliferative disorders (B-CLPDs). In routine practice, partial antigen loss, reduced expression, and unexpected antigen acquisition may create diagnostic difficulty, particularly when tissue-based or molecular confirmation is delayed. This study describes subtype-wise aberrant cluster of differentiation (CD) marker expression patterns in B-CLPDs diagnosed by integrated morphology and multiparameter flow cytometry in a Sri Lankan tertiary-care laboratory. Methods A descriptive cross-sectional analysis was performed on 210 diagnosed B-CLPD cases. Aberrancies were categorized as unexpected expression, antigen loss, or reduced expression using predefined subtype-specific expectations, internal reference populations, and routine laboratory fluorescence-intensity interpretation. Frequencies were reported as N (%) within each subtype, with denominators specified where relevant. Because several rare subtypes had small numbers, inferential testing was restricted to selected comparable aberrancy events between chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Results CLL was the commonest subtype, comprising 94 (44.8%) cases, followed by MCL with 34 (16.2%) and the CD5-negative/CD10-negative/hairy-marker-negative B-CLPD group with 31 (14.8%). In CLL, the most frequent events were unexpected CD20 expression in 44 (46.8%) cases, reduced CD45 in 42 (44.7%), unexpected surface kappa expression in 24 (25.5%), and reduced CD23 in 24 (25.5%). MCL showed reduced CD45 in 11 (32.4%) cases, reduced CD43 in eight (23.5%), reduced CD5 in four (11.7%), unexpected CD23 in four (11.8%), unexpected CD200 in four (11.8%), and reduced FMC7 in four (11.8%). The CD5-negative/CD10-negative/hairy-marker-negative B-CLPD group was the most heterogeneous, with reduced CD200 and reduced FMC7 each occurring in 15 (48.3%) cases. Conclusion CLL was characterized mainly by unexpected CD20 expression and reduced CD45, whereas MCL most commonly showed reduced CD45 and CD43. The CD5-negative/CD10-negative/hairy-marker-negative B-CLPD group showed the greatest immunophenotypic heterogeneity, particularly reduced CD200 and FMC7. These findings demonstrate that aberrant antigen expression is subtype-associated and should be interpreted within the complete immunophenotypic profile rather than using individual markers in isolation.
SN - 2168-8184
ER -